Market news

Motley Fool Press Release.

Moby summary of PAVmed Inc.'s Q2 2026 earnings call

PAVmed Inc (PAVM) reports a significantly reduced net loss, advances the VARIS commercial launch at Ohio State, and explores a faster 510(k) pathway for PortIO.

Detailed price information for Pavmed Inc (PAVM-Q) from The Globe and Mail including charting and trades.

PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid"), Veris Health Inc. ("Veris"), and Octeris Medical Inc. ("Octeris"), and reported financial results for the second quarter ended June 30, 2026.

PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update and discuss the Company's operations and growth strategy. In addition, De

--Lucid Diagnostics Inc., a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc., today announced that it will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update and...